Ascletis Pharma Inc.
1672
Rang in Aktien
#10432
Ascletis Pharma Inc., a biotechnology company, engages in the research and... Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Aktienkurs
$0.75890907
Zuletzt synchronisiert: 2026-10-21
Marktkapitalisierung
$796.59M
Veränderung (1 Tag)
3.53%
Veränderung (1 Jahr)
-34.58%
Land
CN
Handel Ascletis Pharma Inc. (1672)
Kategorie
Healthcare
Kursverlauf für Ascletis Pharma Inc. (1672)
Höchster Schlusskurs: $0.92 am 2026-10-01
Niedrigster Schlusskurs: $0.60 am 2019-11-01
Niedrigster Schlusskurs: $0.60 am 2019-11-01
Kursverlauf der Aktie von Ascletis Pharma Inc. von 2019 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | -10.71% |
| 2025 | 759.36% |
| 2024 | 9.90% |
| 2023 | -65.45% |
| 2022 | 11,939.80% |
| 2021 | -98.81% |
| 2020 | -40.55% |
| 2019 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $136.29 | -4.85% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
